Sls Management buys $7.1 Million stake in Baxalta Inc (BXLT)

Baxalta Inc (BXLT) : Sls Management scooped up 56,877 additional shares in Baxalta Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 166,477 shares of Baxalta Inc which is valued at $7.1 Million.Baxalta Inc makes up approximately 11.91% of Sls Management’s portfolio.

Other Hedge Funds, Including , Altrinsic Global Advisors reduced its stake in BXLT by selling 1,640,202 shares or 64.35% in the most recent quarter. The Hedge Fund company now holds 908,823 shares of BXLT which is valued at $38.5 Million. Baxalta Inc makes up approx 1.07% of Altrinsic Global Advisors’s portfolio.Blackrock Institutional Trust Company N.a. boosted its stake in BXLT in the latest quarter, The investment management firm added 2,221,884 additional shares and now holds a total of 16,748,361 shares of Baxalta Inc which is valued at $710 Million. Baxalta Inc makes up approx 0.12% of Blackrock Institutional Trust Company N.a.’s portfolio.Bahl Gaynor Inc reduced its stake in BXLT by selling 22,986 shares or 50.09% in the most recent quarter. The Hedge Fund company now holds 22,903 shares of BXLT which is valued at $970,858. Baxalta Inc makes up approx 0.01% of Bahl Gaynor Inc’s portfolio.Ngam Advisors boosted its stake in BXLT in the latest quarter, The investment management firm added 1,708 additional shares and now holds a total of 29,246 shares of Baxalta Inc which is valued at $1.2 Million. Baxalta Inc makes up approx 0.02% of Ngam Advisors’s portfolio.Andra Ap-fonden boosted its stake in BXLT in the latest quarter, The investment management firm added 42,900 additional shares and now holds a total of 102,600 shares of Baxalta Inc which is valued at $4.2 Million. Baxalta Inc makes up approx 0.11% of Andra Ap-fonden’s portfolio.

Baxalta Inc opened for trading at $45.48 and hit $45.71 on the upside on Wednesday, eventually ending the session at $45.71, with a gain of 1.58% or 0.71 points. The heightened volatility saw the trading volume jump to 1,26,92,805 shares. Company has a market cap of $31,245 M.

On the company’s financial health, Baxalta Inc reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.46. The company had revenue of $1548.00 million for the quarter, compared to analysts expectations of $1474.42 million. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.40 EPS.

Investors should note that on May 10, 2016, Baxalta Inc announced a cash dividend of $0.0700. The company’s management has announced Jun 8, 2016 as the ex-dividend date and fixed the record date on Jun 10, 2016. The payable date has been fixed on Jul 1, 2016.

Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.

Leave a Reply

Baxalta Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxalta Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.